...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>COPD: Journal of Chronic Obstructive Pulmonary Disease >Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics
【24h】

Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics

机译：普鲁沙星与左氧氟沙星在其他抗生素失效后加重COPD

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The chronic course and evolution of chronic obstructive pulmonary disease (COPD) is often characterized by periods of exacerbation of symptoms, which have a negative impact on the quality of life of patients, as well as on the evolution of COPD, and represent a significant cause of medical intervention and hospitalization. Very few data are available on the efficacy of rescue antibiotics in patients with acute exacerbation of COPD (AECOPD) unresponsive to previous treatment. The aim of this study was to evaluate the efficacy of two fluoroquinolones in AECOPD previously treated without success. The FADOI-FLOR study is a randomized, single-blind, non-inferiority comparison between levofloxacin and prulifloxacin. Primary end-point was "therapeutic success" at Day 10 of treatment, defined as disappearance of signs/symptoms or decrease of at least three points of a global score of symptomatology (maximum score = 15). 258 patients were enrolled (128 levofloxacin and 130 prulifloxacin), in 25 centers. A very high proportion of patients in the two groups had therapeutic success at Day-10 (levofloxacin 93.0% vs prulifloxacin 96.7%, population intention-to-treat; 94.6% vs 99.1%, population per-protocol). Earlier therapeutic success (within 7 days) was achieved in 32.0% and 36.2% of patients receiving levofloxacin or prulifloxacin, respectively. At 3-month follow-up, re-exacerbations occurred in 17.8% of patients treated with levofloxacin and 14.2% of those receiving prulifloxacin (p = 0.44). In conclusion, fluoroquinolones are very effective in the treatment of AECOPD resistant to other antibiotics.
机译：慢性阻塞性肺疾病（COPD）的慢性病程和演变通常以症状加重期为特征，这会对患者的生活质量以及COPD的演变产生负面影响，并且是重要原因医疗干预和住院。关于抢救性抗生素对先前治疗无反应的COPD急性加重（AECOPD）患者疗效的数据很少。这项研究的目的是评估两种氟喹诺酮类药物在先前未成功治疗的AECOPD中的疗效。 FADOI-FLOR研究是左氧氟沙星和普利沙星之间的一项随机，单盲，非劣效性比较。主要终点是治疗第10天的“治疗成功”，定义为体征/症状消失或症状总体评分至少降低三分（最高分= 15）。在25个中心招募了258例患者（左氧氟沙星128例和普利沙星130例）。两组患者中有很高比例的患者在第10天治疗成功（左氧氟沙星93.0％比普利沙星96.7％，人群有意治疗; 94.6％vs 99.1％，每方案人群）。在接受左氧氟沙星或普利沙星治疗的患者中，分别有32.0％和36.2％的患者获得了较早的治疗成功（7天之内）。在3个月的随访中，接受左氧氟沙星治疗的患者和接受普利沙星治疗的患者分别有17.8％和14.2％的病情加重（p = 0.44）。总之，氟喹诺酮类药物在治疗对其他抗生素耐药的AECOPD方面非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号